ABT-751 in Treating Young Patients With Refractory Solid Tumors

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed solid tumor\*, including, but not limited to, the following:
• * Rhabdomyosarcoma
• * Other soft tissue sarcomas
• * Ewing's sarcoma family of tumors
• * Osteosarcoma
• * Neuroblastoma
• * Wilms' tumor
• * Hepatic tumors
• * Germ cell tumors
• * Primary brain tumors
• * Brain stem or optic gliomas (histological confirmation may be waived if a biopsy has not been performed) NOTE: \*Closed to accrual for all diagnoses except neuroblastoma as of 4/16/05
• Relapsed after or failed to respond to frontline standard therapy and no other standard treatment options (e.g., surgery, radiotherapy, chemotherapy, or any combination of these modalities) exist
• Measurable or evaluable disease\* NOTE: \*Not required for patients with neuroblastoma
• No CNS tumor with motor or sensory deficits that would obscure the study assessment of sensory neuropathy
• PATIENT CHARACTERISTICS:
• Age:
• 18 and under
• Performance status:
• Lansky 60-100% (age 10 and under)
• Karnofsky 60-100% (age 11 to 18)
• Life expectancy:
• Not specified
• Hematopoietic:
• Absolute neutrophil count at least 1,500/mm\^3
• Platelet count at least 100,000/mm\^3
• Hepatic:
• Bilirubin no greater than 1.5 times upper limit of normal (ULN)
• ALT and AST no greater than 2.5 times ULN (5 times ULN for patients treated after the maximum tolerated dose is determined)
• No clinically significant hepatic dysfunction
• Renal:
• Creatinine normal for age OR
• Creatinine clearance at least 60 mL/min
• No clinically significant renal dysfunction
• Cardiovascular:
• LVEF normal by echocardiogram
• Other:
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• No allergy to sulfa-containing medications
• No clinically significant unrelated systemic illness (e.g., other organ dysfunction) that would preclude study participation
• No serious infection
• No preexisting grade 2 or greater sensory or motor neuropathy
• HIV negative
• PRIOR CONCURRENT THERAPY:
• Biologic therapy:
• At least 4 months since prior bone marrow transplantation
• At least 72 hours since prior interleukin-11
• At least 72 hours since prior colony-stimulating factors (e.g., filgrastim \[G-CSF\] or sargramostim \[GM-CSF\]) except epoetin alfa
• No concurrent growth factors (e.g., GM-CSF) except epoetin alfa
• * Concurrent G-CSF allowed if neutropenia lasts longer than 5 days OR if the patient experiences confirmed septicemia associated with neutropenia
• No concurrent immunotherapy
• No concurrent interleukin-11
• Chemotherapy:
• See Disease Characteristics
• At least 30 days since prior chemotherapy (42 days for nitrosoureas)
• No other concurrent anticancer chemotherapy
• Endocrine therapy:
• Patients with brain tumors:
• * Must be on a stable or tapering dose of corticosteroids for 7 days before baseline scan performed for the purpose of assessing response to study therapy
• * Concurrent corticosteroids allowed for control of symptoms of tumor-associated edema
• Radiotherapy:
• See Disease Characteristics
• At least 4 weeks since prior radiotherapy
• At least 4 months since prior extensive radiotherapy (craniospinal radiotherapy, total body irradiation, or radiotherapy to more than 50% of the pelvis)
• No concurrent radiotherapy
• Surgery:
• See Disease Characteristics
• Other:
• Recovered from prior therapy
• At least 30 days since prior investigational anticancer therapy
• No other concurrent investigational agents